Modifications of EphA2 expression may alter the susceptibility to Vδ1 γδ T-cell-mediated tumor recognition and killing that might be highly relevant in therapies targeting EphA2 in solid tumors and EphA2-positive leukemia (46). Here, EPHA2 is linked to neoplasm.